Search
for
Sort by
Research 241–270 of 776
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The Role of Janus Kinase Inhibitors in Dermatology
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth